Zelboraf and Proctitis - a phase IV clinical study of FDA data
Summary:
We study 12,775 people who take Zelboraf (vemurafenib) or have Proctitis. No report of Proctitis is found in people who take Zelboraf.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Zelboraf?
Zelboraf has active ingredients of vemurafenib. eHealthMe is studying from 8,392 Zelboraf users. Check the latest studies of Zelboraf.
What is Proctitis?
Proctitis (inflammation of the rectum and anus) is found to be associated with 473 drugs and 615 conditions by eHealthMe. Check the latest studies of Proctitis.
No report is found.
Do you take Zelboraf and have Proctitis?
- Check whether Proctitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Zelboraf:
- Zelboraf (8,392 reports)
Proctitis treatments and more:
- Proctitis (4,383 reports)
How severe was Proctitis and when was it recovered:
Expand to all the drugs that have ingredients of vemurafenib:
Browse all side effects of Zelboraf:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Proctitis:
Browse all the conditions that are associated with Proctitis:
How the study uses the data?
The study uses data from the FDA. It is based on vemurafenib (the active ingredients of Zelboraf) and Zelboraf (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Amitriptyline Hydrochloride and Sudden Death for Men aged 60+ - 16 seconds ago
- Amitriptyline Hydrochloride and Death Sudden for Men aged 60+ - 16 seconds ago
- Amitriptyline Hydrochloride and Death for Men aged 60+ - 17 seconds ago
- Lamotrigine vs. Carbatrol, side effect and effectiveness comparison - 26 seconds ago
- Breast Cancer Stage Ii and drugs of ingredients of golimumab - 32 seconds ago
- Ranitidine and Hair Thinning for Women aged 40-49 - a minute ago
- Ranitidine and Loss Of Hair for Women aged 40-49 - a minute ago
- Ranitidine and Hairloss for Women aged 40-49 - a minute ago
- Ranitidine and Baldness for Women aged 40-49 - a minute ago
- Ranitidine and Alopecia for Women aged 40-49 - a minute ago